Table 4.
Serum level of C‐12 tumor markers in the 3 groups (x ± s)
| Group | Adenocarcinoma (n = 123) | Squamous cell carcinoma (n = 30) | Small‐cell carcinoma (n = 54) |
|---|---|---|---|
| CA199 (U/mL) | 137.11 ± 196.70a | 68.88 ± 146.20b | 37.23 ± 28.55b |
| NSE (ng/mL) | 8.75 ± 12.57 | 5.51 ± 2.90 | 9.11 ± 6.02 |
| CEA (ng/mL) | 40.96 ± 54.10a | 22.68 ± 29.37b | 19.93 ± 25.81b |
| CA242 (U/mL) | 46.87 ± 66.57a | 14.40 ± 20.11b | 13.41 ± 12.04b |
| Ferritin (ng/mL) | 174.64 ± 133.65 | 223.66 ± 126.07 | 185.73 ± 97.71 |
| β‐HCG (ng/mL) | 3.16 ± 10.64 | 0.50 ± 0.40 | 8.21 ± 53.63 |
| AFP (ng/mL) | 9.28 ± 16.69 | 7.28 ± 6.56 | 4.64 ± 4.66 |
| f‐PSA (ng/mL) | 0.24 ± 0.20 | 0.12 ± 0.07 | 0.50 ± 0.69 |
| PSA (ng/mL) | 4.01 ± 17.76 | 0.55 ± 0.39 | 0.99 ± 0.41 |
| CA125 (U/mL) | 179.41 ± 227.12a | 80.46 ± 83.88b | 61.15 ± 81.03b |
| HGH (ng/mL) | 0.27 ± 0.32 | 0.35 ± 0.33 | 0.21 ± 0.11 |
| CA153 (U/mL) | 21.62 ± 37.43a | 19.85 ± 16.78a | 10.82 ± 13.47b |
In the same row, different number (eg, a and b, b and c, a and c) showed there was significant difference between the adenocarcinoma, squamous cell carcinoma and small cell carcinoma (P < .05). In the same row, the same number (eg, a and a, b and b, c and c) showed there was no significant difference between the adenocarcinoma, squamous cell carcinoma and small cell carcinoma (P > .05).